scholarly journals The impact of direct antiviral agents on the development and recurrence of hepatocellular carcinoma

2017 ◽  
Vol 37 ◽  
pp. 136-139 ◽  
Author(s):  
María Reig ◽  
Loreto Boix ◽  
Jordi Bruix
Keyword(s):  
Hepatocellular Carcinoma ◽  
Antiviral Agents ◽  
Direct Antiviral Agents ◽  
The Impact

scholarly journals Hepatocellular Carcinoma Recurrence in HCV Patients Treated with Direct Antiviral Agents

Viruses ◽  
2019 ◽  
Vol 11 (5) ◽  
pp. 406 ◽  
Author(s):  
Marco Sanduzzi-Zamparelli ◽  
Loreto Boix ◽  
Cassia Leal ◽  
María Reig
Keyword(s):  
Hepatocellular Carcinoma ◽  
De Novo ◽  
Antiviral Agents ◽  
The Subject ◽  
Direct Antiviral Agents ◽  
Hepatocellular Carcinoma Recurrence ◽  
Underlying Mechanisms ◽  
Almost All ◽  
The Impact ◽  
Hcc Recurrence

The risk of hepatocellular carcinoma recurrence is universal regardless of the treatment modality applied, and secondary prevention is still an unmet issue even though the elimination of hepatitis C (HCV) with direct antiviral agents (DAAs) was expected to be one of the new options. Unfortunately, the impact of DAAs on hepatocellular carcinoma (HCC) development (de novo and recurrence) is still controversial. Since the first publication on the subject in 2016, almost all groups worldwide have carried out research in this field with hundreds of publications now available. This revision is focused on the impact of DAAs on HCC recurrence and aims to discuss the potential underlying mechanisms and host factors pointing out the time association phenomenon between DAA treatment and HCC recurrence. Moreover, we comment on the methodological issues that could affect the different interpretations of the published results. In conclusion, this is an area of research with potential in the understanding of the impact of factors not previously considered, and may also help change hepatocarcinogenesis tenets, such as the belief that the elimination of HCV should be used as a second prevention treatment.

scholarly journals Changing Patterns of Hepatocellular Carcinoma after Treatment with Direct Antiviral Agents

2020 ◽  
Vol 7 (1-2) ◽  
pp. 50-60
Author(s):  
Mohammed El Fayoumie ◽  
Mahmoud Abdelhady ◽  
Ahmed Gawish ◽  
Usama Hantour ◽  
Ismail Abdelkhaleek ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Antiviral Agents ◽  
Changing Patterns ◽  
Direct Antiviral Agents

scholarly journals Serum miRNA Are Promising Biomarkers for the Detection of Early Hepatocellular Carcinoma after Treatment with Direct-Acting Antivirals

Cancers ◽  
2019 ◽  
Vol 11 (11) ◽  
pp. 1773 ◽  
Author(s):  
Devis Pascut ◽  
Luisa Cavalletto ◽  
Muhammad Yogi Pratama ◽  
Silvia Bresolin ◽  
Luca Trentin ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Random Effect ◽  
Antiviral Agents ◽  
Least Square ◽  
Occurrence Rate ◽  
Patients At Risk ◽  
Early Hcc ◽  
Direct Antiviral Agents ◽  
Direct Acting ◽  
Control Study

Direct antiviral agents (DAAs) have excellent efficacy against chronic hepatitis C virus (HCV) infection. Despite this strength, recent studies raised concerns about an unexpected hepatocellular carcinoma (HCC) occurrence rate after DAA therapy. In this exploratory case-control study, we evaluated the potential use of miRNAs as serum biomarkers for the detection of early HCC in DAA-treated patients. In the discovery phase, the circulating miRNome was assessed in 10 matched patients with (HCC+) or without HCC (HCC−) occurrence. Microarray analysis was performed before (T0) and after one month of the DAA therapy (T1). MiRNAs discriminating HCC+ and HCC− patients were validated in 60 samples by means of RT-qPCR. We estimated the time-averaged difference of a given miRNA between HCC+ and HCC− patients using a bootstrapped random-effect generalized least square regression model (RE-GLS). At T0, miR-1207-5p, miR-1275, miR-3197, miR-4443, miR-3178, miR-483-5p, miR-4706, miR-4793-3p and miR-1246 discriminated HCC+ from HCC− patients (p < 0.05). At T1, only miR-1180-3p, miR-1228-3p, miR-4329 and miR-4484 (p < 0.05) discriminated HCC+ from HCC− patients. The subsequent validation phase identified miR-3197 as changing with both disease and time. Our results suggest that patients might be already committed to HCC occurrence before DAA therapy. MiR-3197 shows some potential for the identification of patients at risk of HCC during DAA treatments.

Sustained virologic response by direct antiviral agents reduces the incidence of hepatocellular carcinoma in patients with HCV infection

2016 ◽  
Vol 89 (3) ◽  
pp. 476-483 ◽  
Author(s):  
Masahiro Kobayashi ◽  
Fumitaka Suzuki ◽  
Shunichiro Fujiyama ◽  
Yusuke Kawamura ◽  
Hitomi Sezaki ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Sustained Virologic Response ◽  
Antiviral Agents ◽  
Virologic Response ◽  
Hcv Infection ◽  
Direct Antiviral Agents

scholarly journals Regression of liver fibrosis and hepatocellular carcinoma development after HCV eradication with oral antiviral agents

2022 ◽  
Vol 12 (1) ◽  
Author(s):  
Hae Won Yoo ◽  
Jun Yong Park ◽  
Sang Gyune Kim ◽  
Young Kul Jung ◽  
Sae Hwan Lee ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Transient Elastography ◽  
Antiviral Agents ◽  
Sustained Viral Response ◽  
Liver Stiffness ◽  
Pegylated Interferon ◽  
Historical Cohort ◽  
Direct Antiviral Agents ◽  
Direct Acting ◽  
Over Time

AbstractWe prospectively investigated the changes of liver stiffness (LS) and the occurrence of hepatocellular carcinoma (HCC) after hepatitis C virus (HCV) eradication using direct antiviral agents (DAA) over three years. LS measurement using transient elastography and serum fibrosis surrogate markers before treatment and at 48, 96, 144 weeks after starting direct-acting antivirals (DAA) according to the protocol were evaluated. Patients were also compared with historical cohort treated with pegylated interferon (peg-IFN). Sustained viral response (SVR) was observed in 95.8%. LS value in the patients achieving SVR significantly decreased over time (19.4 ± 12.9 kPa [baseline], 13.9 ± 9.1 kPa [48 weeks], 11.7 ± 8.2 kPa [96 weeks], 10.09 ± 6.23 [144 weeks], all p < 0.001). With matched analysis, the decrease in LS value was significantly larger in DAA group than peg-IFN group at both 48 weeks (29% vs. 9%) and 96 weeks (39% vs. 17%). The incidence of HCC was not significantly different between DAA and peg-IFN groups (5.5% vs. 5.4%) at 144 weeks. HCV eradication with DAA can lead to improvement of liver stiffness over time. The regression of fibrosis was greater in the group with DAA than peg-IFN.Clinical trials registration: ClinicalTrials.gov (NCT02865369).

Sign in / Sign up

Export Citation Format

Share Document